Di Fabio, Romano published the artcileDiscovery Process and Pharmacological Characterization of 2-(S)-(4-Fluoro-2-methylphenyl)piperazine-1-carboxylic Acid [1-(R)-(3,5-Bis-trifluoromethylphenyl)ethyl]methylamide (Vestipitant) as a Potent, Selective, and Orally Active NK1 Receptor Antagonist, Application of 1-Bromo-4-fluoro-2-methylbenzene, the main research area is piperazine urea aryl asym preparation neurokinin receptor antagonist activity; Vestipitant piperazine NK receptor antagonist pharmacokinetic structure activity relationship.
In an effort to discover novel drug-like NK1 receptor antagonists a new series of suitably substituted C-phenylpiperazine derivatives was identified by an appropriate chem. exploration of related N-phenylpiperazine analogs, with the specific aim to maximize their in vitro affinity and optimize in parallel their pharmacokinetic profile. Among the compounds synthesized, I (Vestipitant) was identified as one of the most in vitro potent and selective NK1 receptor antagonists ever discovered, showing appropriate pharmacokinetic properties and in vivo activity. On the basis of its preclin. profile, I was selected as a drug candidate.
Journal of Medicinal Chemistry published new progress about Anxiety disorders. 452-63-1 belongs to class bromides-buliding-blocks, name is 1-Bromo-4-fluoro-2-methylbenzene, and the molecular formula is C7H6BrF, Application of 1-Bromo-4-fluoro-2-methylbenzene.
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary